Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | MEN1 | O00255 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27814939 | 1.00 | CYP3A4 (0.41) | CYP3A4CYP2D6CYP2C9CYP2C19MAPT | |
| SCHEMBL13618165 | 0.92 | MAPT (0.46) | CYP3A4CYP2D6CYP2C9CYP2C19MAPT | |
| SCHEMBL1134512 | 0.92 | MAPT (0.46) | CYP3A4CYP2D6CYP2C9CYP2C19MAPT | |
| SCHEMBL1134513 | 0.92 | MAPT (0.46) | CYP3A4CYP2D6CYP2C9CYP2C19MAPT | |
| SCHEMBL1134341 | 0.86 | LMNA (0.35) | MAPTALDH1A1MEN1KMT2APOLB | |
| SCHEMBL29284204 | 0.76 | MAPT (0.51) | CYP3A4CYP2D6CYP2C9CYP2C19MAPT | |
| SCHEMBL1700730 | 0.76 | MAPT (0.47) | CYP3A4CYP2D6CYP2C9CYP2C19MAPT | |
| SCHEMBL1134510 | 0.74 | POLB (0.30) | POLB | |
| SCHEMBL3882849 | 0.73 | MEN1 (0.55) | CYP3A4CYP2D6CYP2C9CYP2C19MAPT | |
| SCHEMBL9831080 | 0.73 | ALDH1A1 (0.42) | CYP3A4CYP2D6CYP2C9CYP2C19MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275574-A1 | NOVEL COMPOUNDS-300 | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| US-20090275574-A1 | NOVEL COMPOUNDS-300 | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275574-A1 | NOVEL COMPOUNDS-300 | CACNA1A, SCN10A, OPRM1 | CYP3A4 598/4885CYP2D6 436/4885CYP2C9 685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.